Leadership Team

Tim Boelke, M.D. (CEO/CMO)

Tim graduated as a medical doctor from the Free University of Berlin where he also finished his experimental doctoral thesis in endocrinology. He is a certified pharmaceutical physician (MFPM) and joined the healthcare industry in the late 1980ies. Since then, Tim has held various senior management positions in drug as well as in diagnostics R&D, in marketing and in general management – at local, regional and global level. He has worked in large global organizations such as Roche, Abbott and BASF but also can count on extensive experience in small to medium sized entities (e.g. Hermal, Biocrates).

Dr. Michael Bös (CSO)

Michael has extensive experience in Drug Discovery and Development. Before joining Acousia he served as CSO of the Munich Biotech company Affectis and successfully licensed out two programs in CNS diseases. He held several positions in Medicinal Chemistry at Roche in Basel and Nutley, NJ, USA focusing on CNS disease and Boehringer Ingelheim where he headed the MedChem department in virology research in Laval, Canada. Under his leadership 6 compounds targeting HCV and HIV were granted start of development. He received his PhD in medicinal chemistry from the University of Vienna and did his postdoctoral studies at the ETH Zurich and at Colorado State University in Fort Collins, USA.

Dr. Jonas Dyhrfjeld-Johnsen (CDO)

Jonas has broad experience in inner ear and CNS research and drug development. Before joining Acousia, he served as Head of Pharmacology of the biotech company ReWind Therapeutics in Leuven (Belgium), directing preclinical development programs for remyelinating therapies. He held several positions in preclinical and translational development at Sensorion in Montpellier (France), latest as Vice President of Research and Translational Development. Serving as the scientific and management lead of the companies preclinical and translational programs, he guided two inner ear candidate drugs from early preclinical development into phase 2 clinical trials. He received his PhD in Neuroscience from the Heinrich-Heine University in Düsseldorf (Germany) after an MSc in Biophysics from the University of Copenhagen (Denmark) and did his postdoctoral training at the University of California – Irvine and Harvard Medical School/Massachusetts General Hospital in Boston (USA).